DUBLIN--(BUSINESS WIRE)--The "Esbriet
2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's
offering.
The 5 Key Questions Addressed
- How many physicians were reached by Esbriet through reportable promotional activity in 2017 and how does this compare to its peer set in the Idiopathic Pulmonary Fibrosis market?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
- How does Genentech's depth of coverage vary within key specialties (e.g., Pulmonology, Internal Medicine, and Critical Care Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Esbriet throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most frequent meal recipients and top paid speakers for Esbriet in 2017?
Data Sources & Methodology
- The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals.
- Over 14,300 paid interactions across 4,200 physicians made on behalf of Esbriet were carefully examined to support the analysis.
For more information about this report visit https://www.researchandmarkets.com/research/zmjqkh/esbriet?w=4
